Update on the telavancin activity tested against European staphylococcal clinical isolates (2009–2010)
Authors:
- Rodrigo E. MendesRMRodrigo E. Mendes
- Helio S. SaderHSHelio S. Sader
- David J. FarrellDFDavid J. Farrell
- Ronald N. JonesRJRonald N. Jones
- 1 September 2011
- journal article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 71 (1) , 93-97
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007–2009 studyDiagnostic Microbiology and Infectious Disease, 2011
- Relationship of Vancomycin Minimum Inhibitory Concentration to Mortality in Patients With Methicillin-Resistant Staphylococcus aureus Hospital-Acquired, Ventilator-Associated, or Health-care-Associated PneumoniaChest, 2010
- Telavancin Disrupts the Functional Integrity of the Bacterial Membrane through Targeted Interaction with the Cell Wall Precursor Lipid IIAntimicrobial Agents and Chemotherapy, 2009
- Activity of Telavancin against Staphylococcus aureus Strains with Various Vancomycin Susceptibilities in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial VegetationsAntimicrobial Agents and Chemotherapy, 2009
- Vancomycin MIC plus Heteroresistance and Outcome of Methicillin-Resistant Staphylococcus aureus Bacteremia: Trends over 11 YearsJournal of Clinical Microbiology, 2009
- Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United StatesAntimicrobial Agents and Chemotherapy, 2008
- In Vitro Activity of Telavancin against Resistant Gram-Positive BacteriaAntimicrobial Agents and Chemotherapy, 2008
- In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance InitiativeJournal of Antimicrobial Chemotherapy, 2008
- A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)Therapeutics and Clinical Risk Management, 2008
- High-Dose Vancomycin Therapy for Methicillin-Resistant Staphylococcus aureus InfectionsArchives of internal medicine (1960), 2006